Event category: Concurrent Session

Inherited arrhythmia syndromes and cardiomyopathies pose a significant clinic challenge, with suboptimal treatment and a large unmet need. Over the last decade several new therapies have been developed which target the underlying genetic and molecular causes of these conditions, and many are progressing from pre-clinical research to clinical trials. These discoveries offer a potential paradigm shift in treatment strategies and quality of life for patients. This panel focused on novel genetic and molecular therapies for inherited arrhythmia syndromes and arrhythmogenic cardiomyopathies will bring together experts with a broad range of experience including venture capital, clinicians, translational scientists, and biotech. The session will address a wide range of topics from lab discovery to commercialization.

From life-changing interventions to emotional uncertainties, how does cardiac technology shape the journey of children and young adults with arrhythmias? This session explores the evolving role of electrophysiology (EP) in pediatrics, the impact of cutting-edge devices, and the patient experience—balancing fear, hope, and the promise of innovation. Are we maximizing technology’s potential, or is is there more to uncover in improving outcomes and quality of life for young patients?

This session explores how AI-driven innovations are transforming atrial fibrillation (AF) management, from prevention to long-term care. Experts will discuss AI-powered digital education, solutions for early intervention, and technology’s role in addressing key risk factors like obesity, sleep apnea, and exercise. Is AI the game-changer in achieving sustainable AF care, or just another trend? Join us to find out.